PRO MEDICUS LIMITED (ASX:PME) shares rose nearly 10% after securing two US deals, with RBC Capital Markets saying the wins counter concerns that AI competitors could weaken long-term demand. The contracts include a $16 million, 7-year deal with TidalHealth and a $28 million, 5-year renewal with Allegheny Health Network. RBC kept its “sector perform” rating and $195 target, saying the deals support traction in Pro Medicus’ cloud imaging platform.